Skip to Main Content welcomes new board member, Dr. Ethan Foxman


2 mins

Dr. Ethan Foxman, CEO of Jefferson Radiology and a practicing neuroradiologist who utilizes NeuroQuant in the assessment of neurodegenerative conditions joins Board of Directors

(San Diego, CA) August 6, 2014

CorTechs Lab, Inc. is pleased to announce the addition of a new member to its Board of Directors, Dr. Ethan Foxman. Dr. Foxman received his Ph.D. in Physics from M.I.T. and his M.D. from Stanford University after which he completed fellowship training in neuroradiology at the MGH-Harvard program. He is President & CEO of Jefferson Radiology, a leading radiology practice in the Northeast based in Connecticut, and a founding member of Strategic Radiology. Dr. Foxman has served as Chair of Radiology at multiple hospitals and he is an Adjunct Clinical Professor of Radiology at Stanford University. At Goodwin College he is Chair of the Foundation Board and a member of the Board of Trustees.

“I am happy to join the team and I am enthusiastic about NeuroQuant and future developments at”, said Dr. Foxman. “I have witnessed in our neuroradiology practice the impact of NeuroQuant’s quantitative assessments in the setting of memory disorders and Alzheimer’s disease, and I’m excited by the potential of NeuroQuant to change our approach to neurodegenerative disorders, epilepsy, traumatic brain injury and multiple sclerosis.”

“With his extensive neuroradiology experience, Dr. Foxman brings a wealth of experience to our team at, said Guri Stark, CEO of “We look forward to his advice in helping us set the future direction of quantitative brain imaging and in making NeuroQuant the gold standard for providing brain volume measurements.”

About, Inc. develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k)-cleared and CE-Marked software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA-cleared medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help in the assessment of a variety of neurodegenerative brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. For more information about NeuroQuant and, please visit,

Media Contact:
Shelly Adams, Inc.